Terumo (OTCMKTS:TRUMY) Upgraded at Nomura

Terumo (OTCMKTS:TRUMY) was upgraded by stock analysts at Nomura from a “hold” rating to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

Separately, Zacks Research raised shares of Terumo to a “hold” rating in a report on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy”.

Terumo Stock Down 4.0%

OTCMKTS TRUMY opened at $14.53 on Thursday. The stock’s 50 day moving average is $14.01 and its 200 day moving average is $13.54. The company has a current ratio of 1.59, a quick ratio of 0.97 and a debt-to-equity ratio of 0.06. Terumo has a 12 month low of $12.08 and a 12 month high of $19.60. The stock has a market cap of $21.43 billion, a PE ratio of 23.82 and a beta of 0.68.

Terumo (OTCMKTS:TRUMY) last posted its quarterly earnings results on Friday, May 15th. The company reported $0.11 earnings per share for the quarter, hitting the consensus estimate of $0.11. Terumo had a return on equity of 9.17% and a net margin of 12.09%.The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.84 billion. Research analysts predict that Terumo will post 0.7 EPS for the current fiscal year.

About Terumo

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.